{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:21:57Z","timestamp":1775888517481,"version":"3.50.1"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s11010-023-04816-x","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T13:02:23Z","timestamp":1690894943000},"page":"1895-1908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Possible role of LCZ696 in atherosclerosis: new inroads and perspective"],"prefix":"10.1007","volume":"479","author":[{"given":"Hayder M.","family":"Al-kuraishy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engy","family":"Elekhnawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"192","key":"4816_CR1","doi-asserted-by":"publisher","first-page":"111363","DOI":"10.1016\/j.mad.2020.111363","volume":"1","author":"NN Nalivaeva","year":"2020","unstructured":"Nalivaeva NN, Zhuravin IA, Turner AJ (2020) Neprilysin expression and functions in development, ageing and disease. Mech Ageing Dev 1(192):111363","journal-title":"Mech Ageing Dev"},{"issue":"13","key":"4816_CR2","doi-asserted-by":"publisher","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 8(13):e012272","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"4816_CR3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM (2019) Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"4","key":"4816_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/j.1471-4159.2006.03822.x","volume":"97","author":"R Pardossi-Piquard","year":"2006","unstructured":"Pardossi-Piquard R, Dunys J, Yu G, StGeorge-Hyslop P, Alves da Costa C, Checler F (2006) Neprilysin activity and expression are controlled by nicastrin. J Neurochem 97(4):1052\u20136","journal-title":"J Neurochem"},{"issue":"5","key":"4816_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.healun.2015.12.015","volume":"35","author":"A Bayes-Genis","year":"2016","unstructured":"Bayes-Genis A, Prickett TC, Richards AM, Barallat J, Lup\u00f3n J (2016) Soluble neprilysin retains catalytic activity in heart failure. J Heart Lung Transplant 35(5):684\u2013685","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"4816_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","volume":"65","author":"A Bay\u00e9s-Gen\u00eds","year":"2015","unstructured":"Bay\u00e9s-Gen\u00eds A, Barallat J, Gal\u00e1n A, De Antonio M, Domingo M, Zamora E, Urrutia A, Lup\u00f3n J (2015) Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 65(7):657\u2013665","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4816_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ejhf.435","volume":"18","author":"G Goliasch","year":"2016","unstructured":"Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D (2016) Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail 18(1):89\u201393","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"4816_CR8","first-page":"629","volume":"3","author":"N Vodovar","year":"2015","unstructured":"Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D (2015) Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC 3(8):629\u201336","journal-title":"JACC"},{"key":"4816_CR9","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4328697","author":"D Mishra","year":"2016","unstructured":"Mishra D, Singh S, Narayan G (2016) Role of B cell development marker CD10 in cancer progression and prognosis. Mol Biol Int. https:\/\/doi.org\/10.1155\/2016\/4328697","journal-title":"Mol Biol Int"},{"issue":"11","key":"4816_CR10","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2002-07-2085","volume":"101","author":"D Reynaud","year":"2003","unstructured":"Reynaud D, Lefort N, Manie E, Coulombel L, Levy Y (2003) In vitro identification of human pro-B cells that give rise to macrophages, natural killer cells, and T cells. Blood 101(11):4313\u20134321","journal-title":"Blood"},{"issue":"9","key":"4816_CR11","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"C Visco","year":"2012","unstructured":"Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, Wen W, Liu WM, Kahl BS, d\u2019Amore ES, Montes-Moreno S (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103\u20132113","journal-title":"Leukemia"},{"issue":"2","key":"4816_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ehf2.12607","volume":"7","author":"E Revuelta-L\u00f3pez","year":"2020","unstructured":"Revuelta-L\u00f3pez E, N\u00fa\u00f1ez J, Gastelurrutia P, Cediel G, Januzzi JL, Ibrahim NE, Emdin M, VanKimmenade R, Pascual-Figal D, N\u00fa\u00f1ez E, Gommans F (2020) Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Fail 7(2):559\u2013566","journal-title":"ESC Heart Fail"},{"issue":"7855","key":"4816_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P (2021) The changing landscape of atherosclerosis. Nature 592(7855):524\u2013533","journal-title":"Nature"},{"issue":"10","key":"4816_CR14","doi-asserted-by":"publisher","first-page":"e0205599","DOI":"10.1371\/journal.pone.0205599","volume":"13","author":"PW Fok","year":"2018","unstructured":"Fok PW, Lanzer P (2018) Media sclerosis drives and localizes atherosclerosis in peripheral arteries. PLoS One 13(10):e0205599","journal-title":"PLoS One"},{"issue":"3\u20136","key":"4816_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000504927","volume":"48","author":"JW Roh","year":"2019","unstructured":"Roh JW, Kwon BJ, Ihm SH, Lim S, Park CS, Chang K, Chung WS, Kim DB, Kim SR, Kim HY (2019) Predictors of significant coronary artery disease in patients with cerebral artery atherosclerosis. Cerebrovasc Dis 48(3\u20136):226\u2013235","journal-title":"Cerebrovasc Dis"},{"issue":"12","key":"4816_CR16","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.2337\/dc18-1236","volume":"41","author":"JA Lovshin","year":"2018","unstructured":"Lovshin JA, Bjornstad P, Lovblom LE, Bai JW, Lytvyn Y, Boulet G, Farooqi MA, Santiago S, Orszag A, Scarr D, Weisman A (2018) Atherosclerosis and microvascular complications: results from the canadian study of longevity in type 1 diabetes. Diabetes Care 41(12):2570\u20132578","journal-title":"Diabetes Care"},{"key":"4816_CR17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-057956","author":"HS Schipper","year":"2022","unstructured":"Schipper HS, de Ferranti S (2022) Atherosclerotic cardiovascular risk as an emerging priority in pediatrics. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2022-057956","journal-title":"Pediatrics"},{"issue":"9","key":"4816_CR18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMra2000317","volume":"383","author":"R Vergallo","year":"2020","unstructured":"Vergallo R, Crea F (2020) Atherosclerotic plaque healing. N Engl J Med 383(9):846\u2013857","journal-title":"N Engl J Med"},{"issue":"3","key":"4816_CR19","first-page":"2245","volume":"20","author":"P Shi","year":"2020","unstructured":"Shi P, Ji H, Zhang H, Yang J, Guo R, Wang J (2020) circANRIL reduces vascular endothelial injury, oxidative stress and inflammation in rats with coronary atherosclerosis. Exp Ther Med 20(3):2245\u20132251","journal-title":"Exp Ther Med"},{"issue":"6","key":"4816_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1515\/hsz-2018-0397","volume":"400","author":"M Khosravi","year":"2019","unstructured":"Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M (2019) The effects of oxidative stress on the development of atherosclerosis. Biol Chem 400(6):711\u2013732","journal-title":"Biol Chem"},{"issue":"71","key":"4816_CR21","doi-asserted-by":"publisher","first-page":"100840","DOI":"10.1016\/j.mam.2019.100840","volume":"1","author":"HC Oliveira","year":"2020","unstructured":"Oliveira HC, Vercesi AE (2020) Mitochondrial bioenergetics and redox dysfunctions in hypercholesterolemia and atherosclerosis. Mol Aspects Med 1(71):100840","journal-title":"Mol Aspects Med"},{"issue":"1","key":"4816_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tcm.2018.05.010","volume":"29","author":"A Hartley","year":"2019","unstructured":"Hartley A, Haskard D, Khamis R (2019) Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis\u2013Novel insights and future directions in diagnosis and therapy. Trends Cardiovasc Med 29(1):22\u201326","journal-title":"Trends Cardiovasc Med"},{"key":"4816_CR23","first-page":"2020","volume":"15","author":"C Khatana","year":"2020","unstructured":"Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, Saini AK (2020) Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev 15:2020","journal-title":"Oxid Med Cell Longev"},{"issue":"306","key":"4816_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2020.05.017","volume":"1","author":"H Jinnouchi","year":"2020","unstructured":"Jinnouchi H, Sato Y, Sakamoto A, Cornelissen A, Mori M, Kawakami R, Gadhoke NV, Kolodgie FD, Virmani R, Finn AV (2020) Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. Atherosclerosis 1(306):85\u201395","journal-title":"Atherosclerosis"},{"issue":"5","key":"4816_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/antiox9050362","volume":"9","author":"F Ito","year":"2020","unstructured":"Ito F, Ito T (2020) High-density lipoprotein (Hdl) triglyceride and oxidized HDL: new lipid biomarkers of lipoprotein-related atherosclerotic cardiovascular disease. Antioxidants 9(5):362","journal-title":"Antioxidants"},{"issue":"3","key":"4816_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/HCO.0000000000000839","volume":"36","author":"PK Gill","year":"2021","unstructured":"Gill PK, Dron JS, Hegele RA (2021) Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol 36(3):264\u2013271","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"4816_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","volume":"8","author":"RA Hegele","year":"2020","unstructured":"Hegele RA, Bor\u00e9n J, Ginsberg HN, Arca M, Averna M, Binder CJ, Calabresi L, Chapman MJ, Cuchel M, von Eckardstein A, Frikke-Schmidt R (2020) Rare dyslipidaemias, from phenotype to genotype to management: a European atherosclerosis society task force consensus statement. Lancet Diabetes Endocrinol 8(1):50\u201367","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"4816_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00018-019-03371-3","volume":"77","author":"H Jinnouchi","year":"2020","unstructured":"Jinnouchi H, Guo L, Sakamoto A, Torii S, Sato Y, Cornelissen A, Kuntz S, Paek KH, Fernandez R, Fuller D, Gadhoke N (2020) Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol Life Sci 77(10):1919\u20131932","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"4816_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/biology9030060","volume":"9","author":"AV Poznyak","year":"2020","unstructured":"Poznyak AV, Grechko AV, Orekhova VA, Chegodaev YS, Wu WK, Orekhov AN (2020) Oxidative stress and antioxidants in atherosclerosis development and treatment. Biology 9(3):60","journal-title":"Biology"},{"issue":"1","key":"4816_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-15706-5","volume":"12","author":"F Ho","year":"2022","unstructured":"Ho F, Watson A, Elbatreek MH, Kleikers PW, Khan W, Sourris KC, Dai A, Jha J, Schmidt HH, Jandeleit-Dahm KA (2022) Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis. Sci Rep 12(1):1","journal-title":"Sci Rep"},{"issue":"4","key":"4816_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3390\/ijms21041434","volume":"21","author":"\u00c1 Pejenaute","year":"2020","unstructured":"Pejenaute \u00c1, Cort\u00e9s A, Marqu\u00e9s J, Montero L, Beloqui \u00d3, Fortu\u00f1o A, Mart\u00ed A, Orbe J, Zalba G (2020) NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis. Int J Mol Sci 21(4):1434","journal-title":"Int J Mol Sci"},{"issue":"165","key":"4816_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.yjmcc.2021.12.012","volume":"1","author":"Z Ye","year":"2022","unstructured":"Ye Z, Guo H, Wang L, Li Y, Xu M, Zhao X, Song X, Chen Z, Huang R (2022) GALNT4 primes monocytes adhesion and transmigration by regulating O-Glycosylation of PSGL-1 in atherosclerosis. J Mol Cell Cardiol 1(165):54\u201363","journal-title":"J Mol Cell Cardiol"},{"issue":"60","key":"4816_CR33","doi-asserted-by":"publisher","first-page":"103424","DOI":"10.1016\/j.jff.2019.103424","volume":"1","author":"C Wang","year":"2019","unstructured":"Wang C, Wang H, Zhao Z, Xiao S, Zhao Y, Duan C, Gao L, Li S, Wang J (2019) Pediococcus acidilactici AS185 attenuates early atherosclerosis development through inhibition of lipid regulation and inflammation in rats. J Funct Foods 1(60):103424","journal-title":"J Funct Foods"},{"issue":"15","key":"4816_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.redox.2017.11.027","volume":"1","author":"D He","year":"2018","unstructured":"He D, Zhao M, Wu C, Zhang W, Niu C, Yu B, Jin J, Ji L, Willard B, Mathew AV, Chen YE (2018) Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1. Redox Biol 1(15):228\u2013242","journal-title":"Redox Biol"},{"issue":"1","key":"4816_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"H Zhang","year":"2019","unstructured":"Zhang H, Liu G, Zhou W, Zhang W, Wang K, Zhang J (2019) Neprilysin inhibitor\u2013angiotensin II receptor blocker combination therapy (sacubitril\/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E-deficient Mice. Sci Rep 9(1):1\u20137","journal-title":"Sci Rep"},{"issue":"39","key":"4816_CR36","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/01.hjh.0000746572.65667.fd","volume":"1","author":"Y Suematsu","year":"2021","unstructured":"Suematsu Y, Ideishi A, Tashiro K, Miura SI (2021) Angiotensin receptor-neprilysin inhibitor suppressed cardiac dysfunction by angiogenesis in mice model of atherosclerosis. J Hypertens 1(39):e191","journal-title":"J Hypertens"},{"issue":"13","key":"4816_CR37","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm10132824","volume":"10","author":"SK Chua","year":"2021","unstructured":"Chua SK, Lai WT, Chen LC, Hung HF (2021) The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J Clin Med 10(13):2824","journal-title":"J Clin Med"},{"issue":"11","key":"4816_CR38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","volume":"73","author":"NE Ibrahim","year":"2019","unstructured":"Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC, Iyer S, Januzzi JL (2019) Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol 73(11):1273\u20131284","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"4816_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jchf.2015.03.011","volume":"3","author":"N Vodovar","year":"2015","unstructured":"Vodovar N, Seronde MF, Laribi S, GREAT Network et al (2015) Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail 3(8):629\u2013636","journal-title":"JACC Heart Fail"},{"issue":"9116","key":"4816_CR40","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","volume":"351","author":"JG Cleland","year":"1998","unstructured":"Cleland JG, Swedberg K (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The international ecadotril multi-centre dose-ranging study investigators. Lancet 351(9116):1657\u20131658","journal-title":"Lancet"},{"issue":"9116","key":"4816_CR41","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","volume":"351","author":"JG Cleland","year":"1998","unstructured":"Cleland JG, Swedberg K (1998) Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The Lancet 351(9116):1657\u20131658","journal-title":"The Lancet"},{"issue":"5","key":"4816_CR42","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17(5):510\u2013517","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"4816_CR43","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ndt\/gfu269","volume":"30","author":"P Judge","year":"2015","unstructured":"Judge P, Haynes R, Landray MJ, Baigent C (2015) Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 30(5):738\u2013743","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"4816_CR44","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/1060028015593093","volume":"49","author":"MP Lillyblad","year":"2015","unstructured":"Lillyblad MP (2015) Dual angiotensin receptor and neprilysin inhibition with sacubitril\/valsartan in chronic systolic heart failure: understanding the new PARADIGM. Ann Pharmacother 49(11):1237\u20131251","journal-title":"Ann Pharmacother"},{"issue":"41","key":"4816_CR45","doi-asserted-by":"publisher","first-page":"e30904","DOI":"10.1097\/MD.0000000000030904","volume":"101","author":"Y Chen","year":"2022","unstructured":"Chen Y, He Q, Mo DC, Chen L, Lu JL, Li RX, Huang J (2022) The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: a meta-analysis of randomized controlled trials. Medicine 101(41):e30904","journal-title":"Medicine"},{"issue":"264","key":"4816_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijcard.2018.03.121","volume":"1","author":"V Shi","year":"2018","unstructured":"Shi V, Senni M, Streefkerk H, Modgill V, Zhou W, Kaplan A (2018) Angioedema in heart failure patients treated with sacubitril\/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int J Cardiol 1(264):118\u2013123","journal-title":"Int J Cardiol"},{"issue":"1","key":"4816_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.15420\/cfr.2016:1:1","volume":"2","author":"JT Menendez","year":"2016","unstructured":"Menendez JT (2016) The mechanism of action of LCZ696. Card Fail Rev 2(1):40","journal-title":"Card Fail Rev"},{"issue":"4","key":"4816_CR48","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor\u2014neprilysin inhibitor (ARNi). J Clin Pharmacol 50(4):401\u2013414","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"4816_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54\u201361","journal-title":"Circulation"},{"issue":"4","key":"4816_CR50","first-page":"e131","volume":"9","author":"TH Langenickel","year":"2012","unstructured":"Langenickel TH, Dole WP (2012) Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today 9(4):e131\u2013e139","journal-title":"Drug Discov Today"},{"issue":"7","key":"4816_CR51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.18565\/cardio.2015.7.14-25","volume":"55","author":"ZD Kobalava","year":"2015","unstructured":"Kobalava ZD, Pavlikova EP, Averkov OA, Merai I, Babaeva LA, Amirbegishvili IA, Kotovskaya YV, Moiseev VS (2015) First Experience of clinical application of LCZ696 an AT1-angiotensin receptors and neprilysin inhibitor in patients with chronic heart failure and reduced ejection fraction. Kardiologiia 55(7):14\u201325","journal-title":"Kardiologiia"},{"issue":"16","key":"4816_CR52","doi-asserted-by":"publisher","first-page":"8994","DOI":"10.3390\/ijms22168994","volume":"22","author":"H Sutanto","year":"2021","unstructured":"Sutanto H, Dobrev D, Heijman J (2021) Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias. Int J Mol Sci 22(16):8994","journal-title":"Int J Mol Sci"},{"key":"4816_CR53","doi-asserted-by":"crossref","unstructured":"Nikolic M, Srejovic I, Jovic J, Sretenovic J, Jeremic J, Cekerevac I, Simovic S, Djokovic D, Muric N, Stojic V, Bolevich SS. (2022) Sacubitril\/valsartan in Heart Failure and Beyond\u2014From Molecular Mechanisms to Clinical Relevance. Reviews in Cardiovascular Medicine.","DOI":"10.31083\/j.rcm2307238"},{"key":"4816_CR54","first-page":"174","volume":"10","author":"A Valentim Goncalves","year":"2020","unstructured":"Valentim Goncalves A, Pereira-da-Silva T, Galrinho A, Rio P, Moura Branco L, Soares R, Ilhao Moreira R et al (2020) C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients. Am J Cardiovasc Dis 10:174\u2013181","journal-title":"Am J Cardiovasc Dis"},{"key":"4816_CR55","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1177\/1535370219861283","volume":"244","author":"Q Ge","year":"2019","unstructured":"Ge Q, Zhao L, Ren XM, Ye P, Hu ZY (2019) LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Expe Biol Med 244:1028\u20131039","journal-title":"Expe Biol Med"},{"key":"4816_CR56","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.cardfail.2015.04.014","volume":"21","author":"B Butts","year":"2015","unstructured":"Butts B, Gary RA, Dunbar SB, Butler J (2015) The importance of NLRP3 inflammasome in heart failure. J Card Fail 21:586\u2013593","journal-title":"J Card Fail"},{"key":"4816_CR57","doi-asserted-by":"publisher","first-page":"32926","DOI":"10.1074\/jbc.M114.579961","volume":"289","author":"M Okada","year":"2014","unstructured":"Okada M, Matsuzawa A, Yoshimura A, Ichijo H (2014) The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem 289:32926\u201332936","journal-title":"J Biol Chem"},{"key":"4816_CR58","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10557-020-06995-x","volume":"34","author":"X Li","year":"2020","unstructured":"Li X, Zhu Q, Wang Q, Zhang Q, Zheng Y, Wang L et al (2020) Protection of Sacubitril\/Valsartan against pathological cardiac remodeling by inhibiting the NLRP3 inflammasome after relief of pressure overload in mice. Cardiovasc Drugs Ther 34:629\u2013640","journal-title":"Cardiovasc Drugs Ther"},{"issue":"28","key":"4816_CR59","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.2174\/138161212802481237","volume":"18","author":"A Tuttolomondo","year":"2012","unstructured":"Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G (2012) Atherosclerosis as an inflammatory disease. Curr Pharm Des 18(28):4266\u20134288","journal-title":"Curr Pharm Des"},{"issue":"7","key":"4816_CR60","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/tox.22750","volume":"34","author":"HC Ou","year":"2019","unstructured":"Ou HC, Chou WC, Hung CH, Chu PM, Hsieh PL, Chan SH, Tsai KL (2019) Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway. Environ Toxicol 34(7):825\u2013835","journal-title":"Environ Toxicol"},{"issue":"11","key":"4816_CR61","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.21037\/jtd.2019.10.26","volume":"11","author":"G Wu","year":"2019","unstructured":"Wu G, Zhu Q, Zeng J, Gu X, Miao Y, Xu W, Lv T, Song Y (2019) Extracellular mitochondrial DNA promote NLRP3 inflammasome activation and induce acute lung injury through TLR9 and NF-\u03baB. J Thorac Dis 11(11):4816","journal-title":"J Thorac Dis"},{"issue":"5","key":"4816_CR62","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cmet.2008.08.016","volume":"8","author":"R Gareus","year":"2008","unstructured":"Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M (2008) Endothelial cell-specific NF-\u03baB inhibition protects mice from atherosclerosis. Cell Metab 8(5):372\u2013383","journal-title":"Cell Metab"},{"issue":"5","key":"4816_CR63","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.ajpath.2013.01.022","volume":"182","author":"B Mallavia","year":"2013","unstructured":"Mallavia B, Recio C, Oguiza A, Ortiz-Mu\u00f1oz G, Lazaro I, Lopez-Parra V, Lopez-Franco O, Schindler S, Depping R, Egido J, Gomez-Guerrero C (2013) Peptide inhibitor of NF-\u03baB translocation ameliorates experimental atherosclerosis. Am J Pathol 182(5):1910\u20131921","journal-title":"Am J Pathol"},{"issue":"3","key":"4816_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1568010054022024","volume":"4","author":"N Fujiwara","year":"2005","unstructured":"Fujiwara N, Kobayashi K (2005) Macrophages in inflammation. Current Drug Targets-Inflamm Allergy 4(3):281\u2013286","journal-title":"Current Drug Targets-Inflamm Allergy"},{"issue":"2","key":"4816_CR65","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0006-291X(03)00771-X","volume":"305","author":"T Tabata","year":"2003","unstructured":"Tabata T, Mine S, Kawahara C, Okada Y, Tanaka Y (2003) Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochem Biophys Res Commun 305(2):380\u2013385","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"4816_CR66","doi-asserted-by":"publisher","first-page":"10519","DOI":"10.3390\/ijms221910519","volume":"22","author":"N Akhter","year":"2021","unstructured":"Akhter N, Wilson A, Thomas R, Al-Rashed F, Kochumon S, Al-Roub A, Arefanian H, Al-Madhoun A, Al-Mulla F, Ahmad R, Sindhu S (2021) Ros\/tnf-\u03b1 crosstalk triggers the expression of il-8 and mcp-1 in human monocytic thp-1 cells via the nf-\u03bab and erk1\/2 mediated signaling. Int J Mol Sci 22(19):10519","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4816_CR67","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ptr.6580","volume":"34","author":"N Abedimanesh","year":"2020","unstructured":"Abedimanesh N, Motlagh B, Abedimanesh S, Bathaie SZ, Separham A, Ostadrahimi A (2020) Effects of crocin and saffron aqueous extract on gene expression of SIRT1, AMPK, LOX1, NF-\u03baB, and MCP-1 in patients with coronary artery disease: a randomized placebo-controlled clinical trial. Phytother Res 34(5):1114\u20131122","journal-title":"Phytother Res"},{"issue":"3","key":"4816_CR68","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1002\/jcp.25930","volume":"233","author":"Z Hoseini","year":"2018","unstructured":"Hoseini Z, Sepahvand F, Rashidi B, Sahebkar A, Masoudifar A, Mirzaei H (2018) NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. J Cell Physiol 233(3):2116\u20132132","journal-title":"J Cell Physiol"},{"issue":"2","key":"4816_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.atherosclerosis.2011.08.025","volume":"219","author":"T Djuri\u0107","year":"2011","unstructured":"Djuri\u0107 T, Stankovi\u0107 A, Kon\u010dar I, Radak D, Davidovi\u0107 L, Alavanti\u0107 D, \u017divkovi\u0107 M (2011) Association of MMP-8 promoter gene polymorphisms with carotid atherosclerosis: preliminary study. Atherosclerosis 219(2):673\u2013678","journal-title":"Atherosclerosis"},{"issue":"124","key":"4816_CR70","doi-asserted-by":"publisher","first-page":"110624","DOI":"10.1016\/j.exger.2019.05.013","volume":"1","author":"L Basurto","year":"2019","unstructured":"Basurto L, Gregory MA, Hern\u00e1ndez SB, S\u00e1nchez-Huerta L, Mart\u00ednez AD, Manuel-Apolinar L, Avelar FJ, Alonso LA, S\u00e1nchez-Arenas R (2019) Monocyte chemoattractant protein-1 (MCP-1) and fibroblast growth factor-21 (FGF-21) as biomarkers of subclinical atherosclerosis in women. Exp Gerontol 1(124):110624","journal-title":"Exp Gerontol"},{"issue":"1","key":"4816_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40659-018-0182-7","volume":"51","author":"TA Jacinto","year":"2018","unstructured":"Jacinto TA, Meireles GS, Dias AT, Aires R, Porto ML, Gava AL, Vasquez EC, Pereira TM, Campagnaro BP, Meyrelles SS (2018) Increased ROS production and DNA damage in monocytes are biomarkers of aging and atherosclerosis. Biol Res 51(1):1\u20133","journal-title":"Biol Res"},{"issue":"03","key":"4816_CR72","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4103\/JLP.JLP_26_18","volume":"10","author":"HM Al-Kuraishy","year":"2018","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ (2018) Concept and connotation of oxidative stress in preeclampsia. J Lab Physicians 10(03):276\u2013282","journal-title":"J Lab Physicians"},{"key":"4816_CR73","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8563845","author":"P Marchio","year":"2019","unstructured":"Marchio P, Guerra-Ojeda S, Vila JM, Aldasoro M, Victor VM, Mauricio MD (2019) Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2019\/8563845","journal-title":"Oxid Med Cell Longev"},{"key":"4816_CR74","doi-asserted-by":"publisher","first-page":"108516","DOI":"10.1016\/j.intimp.2021.108516","volume":"6","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NA, Alexiou A, Batiha GE (2022) Neutrophil Extracellular Traps (NETs) and Covid-19: a new frontiers for therapeutic modality. Int Immunopharmacol 6:108516","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"4816_CR75","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/biomedicines8070206","volume":"8","author":"AV Poznyak","year":"2020","unstructured":"Poznyak AV, Grechko AV, Orekhova VA, Khotina V, Ivanova EA, Orekhov AN (2020) NADPH oxidases and their role in atherosclerosis. Biomedicines 8(7):206","journal-title":"Biomedicines"},{"issue":"Suppl 8","key":"4816_CR76","first-page":"S133","volume":"71","author":"NR Hussien","year":"2021","unstructured":"Hussien NR, Al-Niemi MS, Al-Kuraishy HM, Al-Gareeb AI (2021) Statins and Covid-19: the neglected front of bidirectional effects. J Pak Med Assoc 71(Suppl 8):S133\u2013S136","journal-title":"J Pak Med Assoc"},{"issue":"28","key":"4816_CR77","doi-asserted-by":"publisher","first-page":"101338","DOI":"10.1016\/j.redox.2019.101338","volume":"1","author":"SA Manea","year":"2020","unstructured":"Manea SA, Vlad ML, Fenyo IM, Lazar AG, Raicu M, Muresian H, Simionescu M, Manea A (2020) Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis. Redox Biol 1(28):101338","journal-title":"Redox Biol"},{"issue":"3","key":"4816_CR78","doi-asserted-by":"publisher","first-page":"148","DOI":"10.14715\/cmb\/2021.67.3.22","volume":"67","author":"G Lixia","year":"2021","unstructured":"Lixia G, Haiyun Z, Xia Z (2021) The clinical effects of resveratrol on atherosclerosis treatment and its effect on the expression of NADPH oxidase complex genes in vascular smooth muscle cell line. Cell Mol Biol (Noisy-le-grand) 67(3):148\u2013152","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"3","key":"4816_CR79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41569-019-0260-8","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Murugesan P, Huang K, Cai H (2020) NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat Rev Cardiol 17(3):170\u2013194","journal-title":"Nat Rev Cardiol"},{"key":"4816_CR80","doi-asserted-by":"crossref","unstructured":"Al-Thomali AW, Al-Kuraishy HM, Al-Gareeb AI, K. Al-buhadiliy A, De Waard M, Sabatier JM, Khan Khalil AA, Saad HM, Batiha GE. (2022) Role of neuropilin 1 in COVID-19 patients with acute ischemic stroke. Biomedicines. 10(8):2032","DOI":"10.3390\/biomedicines10082032"},{"issue":"37","key":"4816_CR81","doi-asserted-by":"publisher","first-page":"101696","DOI":"10.1016\/j.redox.2020.101696","volume":"1","author":"Y Sun","year":"2020","unstructured":"Sun Y, Lu Y, Saredy J, Wang X, Drummer C IV, Shao Y, Saaoud F, Xu K, Liu M, Yang WY, Jiang X (2020) ROS systems are a new integrated network for sensing homeostasis and alarming stresses in organelle metabolic processes. Redox Biol 1(37):101696","journal-title":"Redox Biol"},{"issue":"1","key":"4816_CR82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/10641963.2018.1441862","volume":"41","author":"M Imran","year":"2019","unstructured":"Imran M, Hassan MQ, Akhtar MS, Rahman O, Akhtar M, Najmi AK (2019) Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats. Clin Exp Hypertens 41(1):62\u201369","journal-title":"Clin Exp Hypertens"},{"issue":"9","key":"4816_CR83","first-page":"916","volume":"5","author":"D Croteau","year":"2020","unstructured":"Croteau D, Qin F, Chambers JM, Kallick E, Luptak I, Panagia M, Pimentel DR, Siwik DA, Colucci WS (2020) Differential effects of sacubitril\/valsartan on diastolic function in mice with obesity-related metabolic heart disease. Basic Transl Sci 5(9):916\u2013927","journal-title":"Basic Transl Sci"},{"issue":"10","key":"4816_CR84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/antiox8100465","volume":"8","author":"VU Nna","year":"2019","unstructured":"Nna VU, Abu Bakar AB, Ahmad A, Eleazu CO, Mohamed M (2019) Oxidative stress, NF-\u03bab-mediated inflammation and apoptosis in the testes of streptozotocin\u2013induced diabetic rats: combined protective effects of malaysian propolis and metformin. Antioxidants 8(10):465","journal-title":"Antioxidants"},{"issue":"1","key":"4816_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-020-01829-y","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, Bai M (2021) CircTM7SF3 contributes to oxidized low-density lipoprotein-induced apoptosis, inflammation and oxidative stress through targeting miR-206\/ASPH axis in atherosclerosis cell model in vitro. BMC Cardiovasc Disord 21(1):1\u20134","journal-title":"BMC Cardiovasc Disord"},{"key":"4816_CR86","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9815039","author":"S Peng","year":"2020","unstructured":"Peng S, Lu XF, Qi YD, Li J, Xu J, Yuan TY, Wu XY, Ding Y, Li WH, Zhou GQ, Wei Y (2020) LCZ696 ameliorates oxidative stress and pressure overload-induced pathological cardiac remodeling by regulating the Sirt3\/MnSOD pathway. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2020\/9815039","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"4816_CR87","doi-asserted-by":"publisher","first-page":"e008268","DOI":"10.1161\/JAHA.117.008268","volume":"7","author":"RK Trivedi","year":"2018","unstructured":"Trivedi RK, Polhemus DJ, Li Z, Yoo D, Koiwaya H, Scarborough A, Goodchild TT, Lefer DJ (2018) Combined angiotensin receptor\u2013neprilysin inhibitors improve cardiac and vascular function via increased no bioavailability in heart failure. J Am Heart Assoc 7(5):e008268","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"4816_CR88","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/hr.2011.39","volume":"34","author":"E Schulz","year":"2011","unstructured":"Schulz E, Gori T, M\u00fcnzel T (2011) Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 34(6):665\u2013673","journal-title":"Hypertens Res"},{"issue":"10","key":"4816_CR89","doi-asserted-by":"publisher","first-page":"e006617","DOI":"10.1161\/JAHA.117.006617","volume":"6","author":"T Seki","year":"2017","unstructured":"Seki T, Goto K, Kansui Y, Ohtsubo T, Matsumura K, Kitazono T (2017) Angiotensin II receptor\u2013neprilysin inhibitor sacubitril\/valsartan improves endothelial dysfunction in spontaneously hypertensive rats. J Am Heart Assoc 6(10):e006617","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"4816_CR90","doi-asserted-by":"publisher","first-page":"9582","DOI":"10.18632\/aging.202692","volume":"13","author":"A Gao","year":"2021","unstructured":"Gao A, Wang Y, Gao X, Tian W (2021) LCZ696 ameliorates lipopolysaccharide-induced endothelial injury. Aging (Albany NY) 13(7):9582","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"4816_CR91","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0008-6363(99)00235-7","volume":"45","author":"MM Kockx","year":"2000","unstructured":"Kockx MM, Herman AG (2000) Apoptosis in atherosclerosis: beneficial or detrimental. Cardiovasc Res 45(3):736\u2013746","journal-title":"Cardiovasc Res"},{"key":"4816_CR92","doi-asserted-by":"publisher","first-page":"105169","DOI":"10.1016\/j.phrs.2020.105169","volume":"166","author":"R Shan","year":"2021","unstructured":"Shan R et al (2021) Apoptosis, autophagy and atherosclerosis: relationships and the role of Hsp27. Pharmacol Res 166:105169","journal-title":"Pharmacol Res"},{"issue":"6","key":"4816_CR93","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00018-018-2983-9","volume":"76","author":"S Paone","year":"2019","unstructured":"Paone S et al (2019) Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci 76(6):1093\u20131106","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"4816_CR94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4070\/kcj.2010.40.7.299","volume":"40","author":"Nam-Ho Kim","year":"2010","unstructured":"Kim Nam-Ho, Kang Peter M (2010) Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J 40(7):299\u2013305","journal-title":"Korean Circ J"},{"key":"4816_CR95","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","volume":"108","author":"Y Xia","year":"2017","unstructured":"Xia Y et al (2017) LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol 108:138\u2013148","journal-title":"J Mol Cell Cardiol"},{"issue":"10","key":"4816_CR96","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nri3520","volume":"13","author":"KJ Moore","year":"2013","unstructured":"Moore KJ, Sheedy FJ, Fisher EA (2013) Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 13(10):709\u2013721","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"4816_CR97","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.redox.2018.09.025","volume":"1","author":"T Yuan","year":"2019","unstructured":"Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, Yuan Q, Yu H, Xu W, Xie X (2019) New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol 1(20):247\u2013260","journal-title":"Redox Biol"},{"issue":"2","key":"4816_CR98","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/HYPERTENSIONAHA.120.16277","volume":"77","author":"K Suzuki","year":"2021","unstructured":"Suzuki K et al (2021) Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction. Hypertension 77(2):546\u2013556","journal-title":"Hypertension"},{"issue":"6","key":"4816_CR99","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.1185","volume":"20","author":"Milton Packer","year":"2018","unstructured":"Packer Milton (2018) Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. Eur J Heart Fail 20(6):973\u2013977","journal-title":"Eur J Heart Fail"},{"key":"4816_CR100","unstructured":"Garc\u00eda RD, Ramirez JM, Peral de Bruno M, Miatello RM, Renna NF. Dual ARB\/NEP Inhibition with LCZ696 improved endothelial regeneration in an experimental model of metabolic syndrome."},{"issue":"5","key":"4816_CR101","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/bbrj.bbrj_105_20","volume":"4","author":"HM Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C (2020) Renin-Angiotensin system and fibrinolytic pathway in COVID-19: one-way skepticism. Biomed Biotechnol Res J (BBRJ) 4(5):33","journal-title":"Biomed Biotechnol Res J (BBRJ)"},{"issue":"185","key":"4816_CR102","doi-asserted-by":"publisher","first-page":"114431","DOI":"10.1016\/j.bcp.2021.114431","volume":"1","author":"C Lugnier","year":"2021","unstructured":"Lugnier C, Al-Kuraishy HM, Rousseau E (2021) PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochem Pharmacol 1(185):114431","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4816_CR103","first-page":"200","volume":"11","author":"HM Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS (2020) Irbesartan attenuates gentamicin-induced nephrotoxicity in rats through modulation of oxidative stress and endogenous antioxidant capacity. Int J Prevent Med 11(3):200\u2013205","journal-title":"Int J Prevent Med"},{"issue":"4","key":"4816_CR104","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/ndt\/gfh030","volume":"19","author":"K Grote","year":"2004","unstructured":"Grote K, Drexler H, Schieffer B (2004) Renin\u2013angiotensin system and atherosclerosis. Nephrol Dial Transplant 19(4):770\u2013773","journal-title":"Nephrol Dial Transplant"},{"issue":"1\u20133","key":"4816_CR105","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0167-0115(00)00178-6","volume":"93","author":"KM Schmidt-Ott","year":"2000","unstructured":"Schmidt-Ott KM, Kagiyama S, Phillips MI (2000) The multiple actions of angiotensin II in atherosclerosis. Regul Pept 93(1\u20133):65\u201377","journal-title":"Regul Pept"},{"issue":"11","key":"4816_CR106","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10495-016-1294-6","volume":"21","author":"X Liu","year":"2016","unstructured":"Liu X, Gao RW, Li M, Si CF, He YP, Wang M, Yang Y, Zheng QY, Wang CY (2016) The ROS derived mitochondrial respirstion not from NADPH oxidase plays key role in Celastrol against angiotensin II-mediated HepG2 cell proliferation. Apoptosis 21(11):1315\u20131326","journal-title":"Apoptosis"},{"issue":"14","key":"4816_CR107","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/cvr\/cvy172","volume":"114","author":"T Jansen","year":"2018","unstructured":"Jansen T, Kr\u00f6ller-Sch\u00f6n S, Sch\u00f6nfelder T, Foretz M, Viollet B, Daiber A, Oelze M, Brandt M, Steven S, Kvandov\u00e1 M, Kalinovic S (2018) \u03b11AMPK deletion in myelomonocytic cells induces a pro-inflammatory phenotype and enhances angiotensin II-induced vascular dysfunction. Cardiovasc Res 114(14):1883\u20131893","journal-title":"Cardiovasc Res"},{"issue":"3","key":"4816_CR108","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4331\/wjbc.v6.i3.209","volume":"6","author":"K Husain","year":"2015","unstructured":"Husain K, Hernandez W, Ansari RA, Ferder L (2015) Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem 6(3):209","journal-title":"World J Biol Chem"},{"key":"4816_CR109","first-page":"13","volume":"1","author":"Y Wu","year":"2022","unstructured":"Wu Y, Liu Y, Zhang L, Wen L, Xie Y (2022) Aconiti lateralis radix praeparata total alkaloids exert anti-RA effects by regulating NF-\u03baB and JAK\/STAT signaling pathways and promoting apoptosis. Front Pharmacol 1:13","journal-title":"Front Pharmacol"},{"issue":"2","key":"4816_CR110","first-page":"111","volume":"2","author":"M Ohishi","year":"2010","unstructured":"Ohishi M, Dusting GJ, Fennessy PA, Mendelsohn FA, Li XC, Zhuo JL (2010) Increased expression and co-localization of ACE, angiotensin II AT1 receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries. Int J Physiol Pathophysiol Pharmacol 2(2):111","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"11","key":"4816_CR111","doi-asserted-by":"publisher","first-page":"107703","DOI":"10.1016\/j.jdiacomp.2020.107703","volume":"34","author":"S Sakurai","year":"2020","unstructured":"Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y (2020) Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis. J Diabetes Complications 34(11):107703","journal-title":"J Diabetes Complications"},{"key":"4816_CR112","unstructured":"valsartan are more effective than ACEIs through attenuation of alternative production of AngII and activation of vasculoprotective AT2R"},{"issue":"13","key":"4816_CR113","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.3390\/ijms22136702","volume":"22","author":"AV Poznyak","year":"2021","unstructured":"Poznyak AV, Bharadwaj D, Prasad G, Grechko AV, Sazonova MA, Orekhov AN (2021) Renin-angiotensin system in pathogenesis of atherosclerosis and treatment of CVD. Int J Mol Sci 22(13):6702","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4816_CR114","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ajh\/hpab108","volume":"35","author":"BI L\u00e9vy","year":"2022","unstructured":"L\u00e9vy BI, Mourad JJ (2022) Renin angiotensin blockers and cardiac protection: from basis to clinical trials. Am J Hypertens 35(4):293\u2013302","journal-title":"Am J Hypertens"},{"issue":"1","key":"4816_CR115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.bbrc.2016.01.142","volume":"471","author":"Y Ding","year":"2016","unstructured":"Ding Y, Chen J, Cui G, Wei Y, Lu C, Wang L, Diao H (2016) Pathophysiological role of osteopontin and angiotensin II in atherosclerosis. Biochem Biophys Res Commun 471(1):5\u20139","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4816_CR116","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2014.07.004","volume":"236","author":"T Wolak","year":"2014","unstructured":"Wolak T (2014) Osteopontin\u2013a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 236(2):327\u2013337","journal-title":"Atherosclerosis"},{"issue":"2","key":"4816_CR117","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12035-014-8756-z","volume":"51","author":"Z Ding","year":"2015","unstructured":"Ding Z, Liu S, Wang X, Khaidakov M, Dai Y, Deng X, Fan Y, Xiang D, Mehta JL (2015) Lectin-like ox-LDL receptor-1 (LOX-1)\u2013Toll-like receptor 4 (TLR4) interaction and autophagy in CATH a differentiated cells exposed to angiotensin II. Mol Neurobiol 51(2):623\u201332","journal-title":"Mol Neurobiol"},{"issue":"9","key":"4816_CR118","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2174\/0929867325666180508100950","volume":"26","author":"AJ Kattoor","year":"2019","unstructured":"Kattoor AJ, Kanuri SH, Mehta JL (2019) Role of Ox-LDL and LOX-1 in atherogenesis. Curr Med Chem 26(9):1693\u20131700","journal-title":"Curr Med Chem"},{"issue":"1","key":"4816_CR119","first-page":"92","volume":"69","author":"T Aoyama","year":"2011","unstructured":"Aoyama T, Minatoguchi S (2011) The effect of ARB on prevention of atherosclerosis. Nihon rinsho Jpn J Clin Med 69(1):92\u20139","journal-title":"Nihon rinsho Jpn J Clin Med"},{"issue":"4","key":"4816_CR120","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000319445","volume":"32","author":"K Husain","year":"2010","unstructured":"Husain K, Suarez E, Isidro A, Ferder L (2010) Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 32(4):296\u2013304","journal-title":"Am J Nephrol"},{"issue":"1","key":"4816_CR121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2004.08.023","volume":"178","author":"V Da Cunha","year":"2005","unstructured":"Da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX (2005) Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 178(1):9\u201317","journal-title":"Atherosclerosis"},{"issue":"1","key":"4816_CR122","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2011.10.013","volume":"220","author":"A Hirohata","year":"2012","unstructured":"Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Hirose E, Kobayashi Y, Ohkawa K, Ohara M (2012) Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis 220(1):134\u2013138","journal-title":"Atherosclerosis"},{"issue":"Supplement_1","key":"4816_CR123","doi-asserted-by":"publisher","first-page":"ehab724","DOI":"10.1093\/eurheartj\/ehab724.020","volume":"42","author":"K Katogiannis","year":"2021","unstructured":"Katogiannis K, Ikonomidis I, Stamouli M, Makavos G, Tsilivarakis D, Koliou G, Vythoulkas D, Tsirigotis P (2021) Effect of sacubitril\/valsartan on left ventricular longitudinal strain in patients with hematologic malignancies after bone marrow transplantation. Eur Heart J 42(Supplement_1):ehab724-020","journal-title":"Eur Heart J"},{"key":"4816_CR124","first-page":"1","volume":"17","author":"S Wei","year":"2022","unstructured":"Wei S, Sun J, Li Y, Xu K, Wang M, Zhang Y (2022) Losartan attenuates atherosclerosis in uremic mice by regulating Treg\/Th17 balance via mediating PTEN\/PI3K\/Akt pathway. Nephron 17:1\u20131","journal-title":"Nephron"},{"issue":"1","key":"4816_CR125","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/liv.14272","volume":"40","author":"G Sanso\u00e8","year":"2020","unstructured":"Sanso\u00e8 G, Aragno M, Wong F (2020) Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Liver Int 40(1):18\u201331","journal-title":"Liver Int"},{"issue":"30","key":"4816_CR126","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.2174\/0929867324666170414162841","volume":"24","author":"L Anguiano","year":"2017","unstructured":"Anguiano L, Riera M, Pascual J, Soler MJ (2017) Circulating ACE2 in cardiovascular and kidney diseases. Curr Med Chem 24(30):3231\u20133241","journal-title":"Curr Med Chem"},{"issue":"1","key":"4816_CR127","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2012.08.018","volume":"226","author":"Y Wang","year":"2013","unstructured":"Wang Y, Tikellis C, Thomas MC, Golledge J (2013) Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis 226(1):3\u20138","journal-title":"Atherosclerosis"},{"issue":"244","key":"4816_CR128","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2015.11.017","volume":"1","author":"F Bossi","year":"2016","unstructured":"Bossi F, Bernardi S, De Nardo D, Bramante A, Candido R, Carretta R, Fischetti F, Fabris B (2016) Angiotensin 1\u20137 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro. Atherosclerosis 1(244):121\u2013130","journal-title":"Atherosclerosis"},{"key":"4816_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13389","author":"FH AlAnazi","year":"2019","unstructured":"AlAnazi FH, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Ogaly HA, Alanazi YA, Saad HM, Batiha GE (2019) Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: controversial points and a promising arena. J Diabetes. https:\/\/doi.org\/10.1111\/1753-0407.13389","journal-title":"J Diabetes"},{"issue":"4","key":"4816_CR130","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","volume":"24","author":"Y Suematsu","year":"2018","unstructured":"Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H (2018) LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J Cardiac Fail 24(4):266\u2013275","journal-title":"J Cardiac Fail"},{"key":"4816_CR131","unstructured":"Renna NF, Ramirez JM, Garcia RD, Miatello RM. (2018) Role of Insulin Resistance in Vascular Inflammation. InUltimate Guide to Insulin . IntechOpen"},{"issue":"2","key":"4816_CR132","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cpt.455","volume":"101","author":"J Jordan","year":"2017","unstructured":"Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, Havekes B, Schindler C, Albrecht D, Pal P, Heise T (2017) Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther 101(2):254\u2013263","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4816_CR133","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1210\/er.2018-00141","volume":"40","author":"A Di Pino","year":"2019","unstructured":"Di Pino A, DeFronzo RA (2019) Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocr Rev 40(6):1447\u20131467","journal-title":"Endocr Rev"},{"issue":"5","key":"4816_CR134","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/jhh.2010.73","volume":"25","author":"M Kurata","year":"2011","unstructured":"Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M, Miyoshi K, Desilva VR, Higaki J (2011) Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J Hum Hypertens 25(5):334\u2013339","journal-title":"J Hum Hypertens"},{"issue":"Suppl 3","key":"4816_CR135","doi-asserted-by":"publisher","first-page":"A23","DOI":"10.1136\/heartjnl-2011-300867.66","volume":"97","author":"C Song","year":"2011","unstructured":"Song C, Hongbing Y, Shujuan C, Shuzheng L, Yundai C, Guoxiang H, Xiantao S, Zening J, Lijun M, CuiSong V (2011) The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice. Heart 97(Suppl 3):A23\u2013A24","journal-title":"Heart"},{"issue":"1","key":"4816_CR136","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/diagnostics13010016","volume":"13","author":"A Martyniak","year":"2023","unstructured":"Martyniak A, Tomasik PJ (2023) A New perspective on the renin-angiotensin system. Diagnostics 13(1):16","journal-title":"Diagnostics"},{"issue":"63","key":"4816_CR137","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2013.07.010","volume":"1","author":"J Mori","year":"2013","unstructured":"Mori J, Zhang L, Oudit GY, Lopaschuk GD (2013) Impact of the renin\u2013angiotensin system on cardiac energy metabolism in heart failure. J Mol Cell Cardiol 1(63):98\u2013106","journal-title":"J Mol Cell Cardiol"},{"key":"4816_CR138","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","volume":"28","author":"H Kusaka","year":"2015","unstructured":"Kusaka H et al (2015) LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens 28:1409\u20131417","journal-title":"Am J Hypertens"},{"issue":"6","key":"4816_CR139","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.amjcard.2017.06.030","volume":"120","author":"DK Gupta","year":"2017","unstructured":"Gupta DK, Daniels LB, Cheng S, deFilippi CR, Criqui MH, Maisel AS, Lima JA, Bahrami H, Greenland P, Cushman M, Tracy R (2017) Differences in natriuretic peptide levels by race\/ethnicity (from the multi-ethnic study of atherosclerosis). Am J Cardiol 120(6):1008\u20131015","journal-title":"Am J Cardiol"},{"key":"4816_CR140","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1291\/hypres.31.575","volume":"31","author":"T Imanishi","year":"2008","unstructured":"Imanishi T et al (2008) Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. Hypertens Res 31:575\u2013584","journal-title":"Hypertens Res"},{"key":"4816_CR141","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ et al (2014) Angiotensin- neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"key":"4816_CR142","first-page":"736","volume":"19","author":"K Hayashi","year":"2012","unstructured":"Hayashi K, Sasamura H, Azegami T, Itoh H (2012) Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. J Atheroscler Thromb 19:736\u2013746","journal-title":"J Atheroscler Thromb"},{"key":"4816_CR143","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet 380:1387\u20131395","journal-title":"Lancet"},{"key":"4816_CR144","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ahj.2017.02.034","volume":"188","author":"UM Mogensen","year":"2017","unstructured":"Mogensen UM et al (2017) The effects of sacubitril\/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J 188:35\u201341","journal-title":"Am Heart J"},{"issue":"Supplement_G","key":"4816_CR145","doi-asserted-by":"publisher","first-page":"suab130","DOI":"10.1093\/eurheartj\/suab130.008","volume":"23","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, Buccolo S, Iovine M, Maurea F, Rea D, Barbieri A, Maurea N (2021) 54 Sacubitril\u2013valsartan (LCZ 696) improves longitudinal strain and ejection fraction in preclinical models treated with doxorubicin through NLRP3, MyD88, and pro-fibrotic chemokines. Eur Heart J Suppl 23(Supplement_G):suab130-008","journal-title":"Eur Heart J Suppl"},{"issue":"4","key":"4816_CR146","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.thromres.2005.04.008","volume":"117","author":"S Nomura","year":"2006","unstructured":"Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T (2006) Effect of valsartan on monocyte\/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 117(4):385\u2013392","journal-title":"Thromb Res"},{"issue":"1\u20132","key":"4816_CR147","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cccn.2004.12.006","volume":"355","author":"QZ Li","year":"2005","unstructured":"Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP (2005) Valsartan reduces interleukin-1\u03b2 secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 355(1\u20132):131\u2013136","journal-title":"Clin Chim Acta"},{"issue":"2","key":"4816_CR148","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1097\/MJT.0000000000000473","volume":"24","author":"S Yandrapalli","year":"2017","unstructured":"Yandrapalli S, Aronow WS, Mondal P, Chabbott DR (2017) Limitations of sacubitril\/valsartan in the management of heart failure. Am J Ther 24(2):e234\u2013e239","journal-title":"Am J Ther"},{"key":"4816_CR149","doi-asserted-by":"publisher","first-page":"H617","DOI":"10.1152\/ajpheart.00177.2019","volume":"317","author":"A Sorrentino","year":"2019","unstructured":"Sorrentino A, Steinhorn B, Troncone L (2019) Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress. Am J Physiol Heart Circ Physiol 317:H617\u2013H626","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"4816_CR150","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ejhf.799","volume":"19","author":"E D'Elia","year":"2017","unstructured":"D\u2019Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M (2017) Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 19:710\u2013717","journal-title":"Eur J Heart Fail"},{"key":"4816_CR151","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2165\/11589400-000000000-00000","volume":"11","author":"E Cangiano","year":"2011","unstructured":"Cangiano E, Marchesini J, Campo G, Francolini G, Fortini C, Carr\u00e0 G, Miccoli M, Ceconi C, Tavazzi L, Ferrari R (2011) ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs 11:189\u2013198","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"4816_CR152","first-page":"1159","volume":"21","author":"ZC Wang","year":"2017","unstructured":"Wang ZC, Qi J, Liu LM, Li J, Xu HY, Liang B, Li B (2017) Valsartan reduces AT1-AA-induced apoptosis through suppression oxidative stress mediated ER stress in endothelial progenitor cells. Eur Rev Med Pharmacol Sci 21(5):1159\u20131168","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"4816_CR153","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.amjcard.2019.04.030","volume":"124","author":"N Madan","year":"2019","unstructured":"Madan N, Lee AK, Matsushita K, Hoogeveen RC, Ballantyne CM, Selvin E, McEvoy JW (2019) Relation of isolated systolic hypertension and pulse pressure to high-sensitivity cardiac troponin-T and N-terminal pro-B-type natriuretic peptide in older adults (from the atherosclerosis risk in communities study). Am J Cardiol 124(2):245\u2013252","journal-title":"Am J Cardiol"},{"key":"4816_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.547365","author":"J Liu","year":"2020","unstructured":"Liu J, Lin Q, Guo D, Yang Y, Zhang X, Tu J, Ning X, Song Y, Wang J (2020) Association between pulse pressure and carotid intima-media thickness among low-income adults aged 45 years and older: a population-based cross-sectional study in rural China. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2020.547365","journal-title":"Front Cardiovasc Med"},{"key":"4816_CR155","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8867578","author":"L Zheng","year":"2021","unstructured":"Zheng L, Xia B, Zhang X, Zhao Y (2021) A meta-analysis on the effect and safety of LCZ696 in the treatment of hypertension. Cardiol Res Pract. https:\/\/doi.org\/10.1155\/2021\/8867578","journal-title":"Cardiol Res Pract"},{"issue":"3","key":"4816_CR156","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1002\/iid3.798","volume":"11","author":"AA Alsaidan","year":"2023","unstructured":"Alsaidan AA, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayed KA, Saad HM, Batiha GE (2023) The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread. Immun Inflamm Dis 11(3):e798","journal-title":"Immun Inflamm Dis"},{"key":"4816_CR157","first-page":"1","volume":"9","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE (2023) The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology 9:1\u20132","journal-title":"Inflammopharmacology"},{"issue":"2","key":"4816_CR158","first-page":"1434","volume":"22","author":"OM Sami","year":"2022","unstructured":"Sami OM, Shams HA, Aziz HM, Al-kuraishy HM (2022) The Substantial effects of statins therapy on PCSK9 and adipocytokine in dyslipidemic non-diabetic patients: prevailing motive. HIV Nursing 22(2):1434\u20131439","journal-title":"HIV Nursing"},{"issue":"9","key":"4816_CR159","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3390\/ph15091147","volume":"15","author":"BM Alomair","year":"2022","unstructured":"Alomair BM, Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, De Waard M, Sabatier JM, Saad HM, El-Saber BG (2022) Montelukast and acute coronary syndrome: the endowed drug. Pharmaceuticals 15(9):1147","journal-title":"Pharmaceuticals"},{"key":"4816_CR160","first-page":"1","volume":"8","author":"SS Alkhayyat","year":"2022","unstructured":"Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE, Simal-Gandara J (2022) Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflamm Res 8:1\u20139","journal-title":"Inflamm Res"},{"issue":"5","key":"4816_CR161","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10787-022-01038-3","volume":"30","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Negm WA, Alexiou A, Batiha GE (2022) Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective. Inflammopharmacology 30(5):1493\u20131501","journal-title":"Inflammopharmacology"},{"key":"4816_CR162","doi-asserted-by":"publisher","first-page":"e01407","DOI":"10.1016\/j.sciaf.2022.e01407","volume":"22","author":"GE Batiha","year":"2022","unstructured":"Batiha GE, Al-Gareeb AI, Rotimi D, Adeyemi OS, Al-Kuraishy HM (2022) Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer. Scientific African 22:e01407","journal-title":"Scientific African"},{"issue":"13","key":"4816_CR163","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/jcmm.17784","volume":"27","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Jabir MS, Saad HM, Batiha GE (2023) NF-\u03baB\/NLRP3 inflammasome axis and risk of Parkinson\u2019s disease in Type 2 diabetes mellitus: a narrative review and new perspective. J Cell Mol Med 27(13):1775\u20131789","journal-title":"J Cell Mol Med"},{"issue":"6","key":"4816_CR164","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s10787-022-01070-3","volume":"30","author":"GE Batiha","year":"2022","unstructured":"Batiha GE, Al-Gareeb AI, Elekhnawy E, Al-Kuraishy HM (2022) Potential role of lipoxin in the management of COVID-19: a narrative review. Inflammopharmacology 30(6):1993\u20132001","journal-title":"Inflammopharmacology"},{"issue":"3","key":"4816_CR165","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2174\/1389203723666220512104039","volume":"23","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE (2022) COVID-19 and L-arginine supplementations: yet to find the missed key. Curr Protein Pept Sci 23(3):166\u2013169","journal-title":"Curr Protein Pept Sci"},{"issue":"5","key":"4816_CR166","doi-asserted-by":"publisher","first-page":"FSO797","DOI":"10.2144\/fsoa-2021-0099","volume":"8","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Fageyinbo MS, Batiha GE (2022) Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19. Future Sci OA 8(5):FSO797","journal-title":"Future Sci OA"},{"key":"4816_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-022-01087-8","volume":"19","author":"GE Batiha","year":"2023","unstructured":"Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Ashour NA, Negm WA (2023) Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Inflammopharmacology 19:1\u20131","journal-title":"Inflammopharmacology"},{"issue":"6","key":"4816_CR168","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s10787-022-01080-1","volume":"30","author":"AO Babalghith","year":"2022","unstructured":"Babalghith AO, Al-Kuraishy HM, Al-Gareeb AI, De Waard M, Al-Hamash SM, Jean-Marc S, Negm WA, Batiha GE (2022) The role of berberine in Covid-19: potential adjunct therapy. Inflammopharmacology 30(6):2003\u20132016","journal-title":"Inflammopharmacology"},{"issue":"152","key":"4816_CR169","doi-asserted-by":"publisher","first-page":"113225","DOI":"10.1016\/j.biopha.2022.113225","volume":"1","author":"M Alorabi","year":"2022","unstructured":"Alorabi M, Cavalu S, Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, Negm WA, Youssef A, El-Kadem AH, Saad HM, Batiha GE (2022) Pentoxifylline and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress. Biomed Pharmacother 1(152):113225","journal-title":"Biomed Pharmacother"},{"issue":"Suppl 1","key":"4816_CR170","first-page":"11","volume":"10","author":"HA Rasheed","year":"2020","unstructured":"Rasheed HA, Al-Naimi MS, Hussien NR, Al-Harchan NA, Al-Kuraishy HM, Al-Gareeb AI (2020) New insight into the effect of lycopene on the oxidative stress in acute kidney injury. Int J Crit Illn Inj Sci 10(Suppl 1):11","journal-title":"Int J Crit Illn Inj Sci"},{"issue":"1","key":"4816_CR171","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/ijpvm.IJPVM_5_19","volume":"10","author":"HM Al-Kuraishy","year":"2019","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Nami MS (2019) Vinpocetine improves oxidative stress and pro-inflammatory mediators in acute kidney injury. Int J Prev Med 10(1):142","journal-title":"Int J Prev Med"},{"issue":"2","key":"4816_CR172","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4103\/bbrj.bbrj_7_20","volume":"4","author":"MH Abdul-Hadi","year":"2020","unstructured":"Abdul-Hadi MH, Naji MT, Shams HA, Sami OM, Al-Harchan NA, Al-Kuraishy HM, Al-Gareeb AI (2020) Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin. Biomed Biotechnol Res J (BBRJ) 4(2):166","journal-title":"Biomed Biotechnol Res J (BBRJ)"},{"key":"4816_CR173","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1007\/s11010-021-04232-z","volume":"476","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Cruz-Martins N, Batiha GE (2021) The potential role of neopterin in Covid-19: a new perspective. Mol Cell Biochem 476:4161\u20134166","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"4816_CR174","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/jioh.jioh_158_19","volume":"11","author":"SS Kadhim","year":"2019","unstructured":"Kadhim SS, Al-Windy SA, Al-Kuraishy HM, Al-Gareeb AI (2019) Endothelin-1 is a surrogate biomarker link severe periodontitis and endothelial dysfunction in hypertensive patients: the potential nexus. J Int Oral Health 11(6):369","journal-title":"J Int Oral Health"},{"issue":"10","key":"4816_CR175","doi-asserted-by":"publisher","first-page":"2200188","DOI":"10.1002\/ardp.202200188","volume":"355","author":"HM Al-kuraishy","year":"2022","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GE (2022) Ginkgo biloba in the management of the COVID-19 severity. Arch Pharm 355(10):2200188","journal-title":"Arch Pharm"},{"key":"4816_CR176","first-page":"1","volume":"15","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE (2022) An insight into the placental growth factor (PlGf)\/angii axis in Covid-19: a detrimental intersection. Biotechnol Genet Eng Rev 15:1\u201320","journal-title":"Biotechnol Genet Eng Rev"},{"key":"4816_CR177","first-page":"1","volume":"31","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J (2022) Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology 31:1","journal-title":"Inflammopharmacology"},{"issue":"12","key":"4816_CR178","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3390\/diagnostics12122985","volume":"12","author":"HM Saad","year":"2022","unstructured":"Saad HM, Tourky GF, Al-Kuraishy HM, Al-Gareeb AI, Khattab AM, Elmasry SA, Alsayegh AA, Hakami ZH, Alsulimani A, Sabatier JM, Eid MW (2022) The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity. Diagnostics 12(12):2985","journal-title":"Diagnostics"},{"issue":"1","key":"4816_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-022-00900-2","volume":"14","author":"GE Batiha","year":"2022","unstructured":"Batiha GE, Al-Kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Saad HM, Al-Gareeb AI, Simal-Gandara J (2022) Plasminogen activator inhibitor 1 and gestational diabetes: the causal relationship. Diabetol Metab Syndr 14(1):1\u20136","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"4816_CR180","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1871530322666220801102402","volume":"23","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Harcan NA, Alexiou A, Batiha GE (2023) Tranexamic acid and plasminogen\/plasmin glaring paradox in COVID-19. Endocr Metab Immune Disord Drug Targets 23(1):35\u201345","journal-title":"Endocr Metab Immune Disord Drug Targets"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-023-04816-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-023-04816-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:55:18Z","timestamp":1724435718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-023-04816-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":180,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1007\/s11010-023-04816-x","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}